Indications & formulation #
Alcohol dependence and relapse prevention after opioid detoxification. This reference covers the selected formulation; other indications and products need their own evidence.
Dose reference #
Adult educational reference · Oral tablet · United States. The clinician selects treatment after assessment; this page does not calculate or change a prescription.
Alcohol-dependence label reference: 50 mg/day within a psychosocial program. For opioid dependence, initiation is clinician-supervised after establishing an adequate opioid-free interval.
Contraindications & important cautions #
Avoid current opioid use/dependence, acute withdrawal or failed opioid challenge. Precipitated withdrawal may be severe.
Selected important cautions; consult the full product information for all contraindications and warnings.
Adverse effects #
Nausea, precipitated withdrawal and hepatic concerns.
Interactions #
Blocks opioid analgesia; treatment requires an opioid-free assessment.
Monitoring #
Review liver symptoms, opioid exposure, drinking and recovery goals.
Special populations #
Assess hepatic injury and renal impairment. Longer opioid-free intervals may be needed after methadone/buprenorphine.
Adult scope. Pregnancy, breastfeeding and pediatric use require the exact product’s population-specific guidance and individual assessment.
Discontinuation, restarting & counseling #
Discuss reduced opioid tolerance, overdose vulnerability after stopping, pain-care planning and access to naloxone.
Condition-specific prescribing #
Additional indication-specific records retain their own formulation and source context.
Naltrexone
Relapse prevention following assisted alcohol withdrawal
Adults · Oral tablets · Oral · UK NICE regimen plus US label opioid precautions; Indian authorization not established here.
- Starting dose
- 25 mg once daily under the NICE initiation approach.
- Titration
- Increase toward 50 mg once daily after assessing tolerability; NICE does not specify a universal day-by-day increment.
- Treatment range / target
- 50 mg once daily.
- Maximum / limits
- 50 mg/day is the routine AUD regimen shown; no higher-dose schedule is inferred.
- Trial & duration
- Usually up to 6 months; extend when benefiting and desired.
- Monitoring
- Baseline hepatic assessment; review symptoms of hepatitis, adherence, drinking and analgesia needs.
- Population & organ-function adjustments
- Significant hepatic or renal impairment requires product-specific assessment; no empirical adjustment formula.
- Important cautions
- Exclude current opioid use/dependence. US label recommends at least 7–10 opioid-free days after short-acting opioids; vulnerability after methadone/buprenorphine may last longer. This interval alone does not establish suitability.
Brands & products #
Historical catalogue observations. Prices and catalogue presence do not establish current availability or Indian approval.
Reference coverage #
Structured summary of selected adult uses, not an exhaustive monograph. Indian product authorization and local prescribing requirements have not been reconciled.
References · 3
- Naltrexone — Oral tablet — selected prescribing information · United States · Checked 2026-10-27 · Selected formulation: Oral tablet · Supports indications, dose, cautions, adverse effects, interactions, monitoring, special populations and stopping. Source sections: Indications and usage; Dosage and administration; Contraindications; warnings and precautions; Use in specific populations; patient counseling
- NICE CG115: alcohol dependence · United Kingdom · Checked 2026-10-26 · Supports: Naltrexone — Relapse prevention following assisted alcohol withdrawal (Oral tablets)
- Naltrexone tablets: US label · United States; DailyMed submitted label · Checked 2026-10-26 · Supports: Naltrexone — Relapse prevention following assisted alcohol withdrawal (Oral tablets)